DBS Programming for Essential Tremor
Trial Summary
What is the purpose of this trial?
Population Size and Eligible Patients: The investigators aim to recruit 5 to 10 patients with tremors who have previously undergone Ventral Intermedius Deep Brain Stimulation (VIM-DBS) treatment but have experienced early or late loss of benefits. Additionally, the investigators will enroll ten patients with essential tremor who require VIM-DBS surgery. These individuals will undergo bilateral implantation of Boston Scientific Genus Implantable Pulse Generator (IPG) devices, connected to Boston Scientific Cartesia™ 8-contact Directional Leads. Study Design: This study comprises two distinct phases. Phase 1 is a cross-sectional investigation designed to identify the optimal algorithm for patterned stimulation in the VIM region . Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor. Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, the investigators seek to explore the impact of the Chronos programming software on tremor patients who have experienced early or late loss of benefits.
Will I have to stop taking my current medications?
The trial requires that you stay on a stable dose of your anti-tremor medication for at least 4 weeks before screening. So, you should not stop taking your current medications.
What data supports the effectiveness of the treatment Directional Bilateral Thalamic Patterned Stimulation for Essential Tremor?
Research suggests that using directional current steering and short pulse stimulation in the thalamus can reduce side effects in essential tremor patients, indicating potential benefits of this approach. Additionally, symmetric biphasic pulses, which are part of the treatment, have been shown to enlarge the therapeutic window, potentially improving effectiveness.12345
Is DBS programming for essential tremor generally safe in humans?
Deep brain stimulation (DBS) for essential tremor has been studied for long-term safety, showing that while it can be effective, there are risks such as mild side effects that can be managed with adjustments, and device-related complications that may require additional surgeries. Some patients experienced asymptomatic brain bleeds and seizures, but these were not common.23567
How is the Directional Bilateral Thalamic Patterned Stimulation treatment different from other treatments for essential tremor?
Eligibility Criteria
This trial is for patients with tremors, specifically those who have had VIM-DBS treatment but lost its benefits and those needing new VIM-DBS surgery. Up to 20 people will be enrolled, all of whom must have essential tremor and agree to receive a specific device implant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 - Cross-sectional Investigation
Identify the optimal algorithm for patterned stimulation in the VIM region for patients with early or late loss of benefits from previous VIM-DBS treatment.
Phase 2 - Prospective Clinical Trial
Assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor, with programming in four different settings over 8 months.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Directional Bilateral Thalamic Patterned Stimulation
Directional Bilateral Thalamic Patterned Stimulation is already approved in United States, European Union, Canada for the following indications:
- Essential Tremor
- Parkinsonian Tremor
- Essential Tremor
- Parkinsonian Tremor
- Dystonic Tremor
- Essential Tremor
- Parkinsonian Tremor
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alfonso Fasano
Lead Sponsor
Boston Scientific Corporation
Industry Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology